|
India’s First Indigenous African Swine Fever Vaccine
Scientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) develop India’s first indigenous African Swine Fever (ASF) vaccine. The vaccine is reported as a live attenuated, MA-104 cell line-based vaccine, in the context of ASF affecting domestic and wild pigs.
Indigenous African Swine Fever (ASF) Vaccine:
| Dimension | Key Details |
|---|---|
| Developing institution | The vaccine is developed by ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD). |
| Vaccine type and platform | The vaccine comprises a live attenuated, MA-104 cell line-based vaccine. |
| Significance | The vaccine authorises enhanced disease preparedness, protection of pig farmers' livelihoods, support to the swine industry, and strengthening of India's veterinary biotechnology capabilities. |
| ASF nature | ASF comprises a highly contagious viral disease. |
| Causative agent | African Swine Fever Virus (ASFV) comprises the causative agent of ASF. |
| Species affected | To domestic and wild pigs only. |
| Mortality | To mortality that may reach 100%. |
| Human health risk | No risk to human health. |
| Economic impact | Severe economic losses. |
| Transmission routes | ASF transmission comprises infected pigs, contaminated pork products, fomites, and soft ticks. |